Nanoceria: a Potential Therapeutic for Dry AMD

Adv Exp Med Biol. 2016:854:111-8. doi: 10.1007/978-3-319-17121-0_16.

Abstract

Age-related macular degeneration (AMD) is the leading cause of blinding diseases. The "dry" form of AMD is the most common form of AMD. In contrast to the treatable neovascular (wet) AMD, no effective treatment is available for dry AMD. In this review, we summarize the animal models and therapeutic strategies for dry AMD. The novel candidates as potential treatment targets and the potential effectiveness of nanoceria as a treatment of dry AMD are also discussed.

Keywords: Animal models; Drusen; Dry AMD; Nanoceria; RPE; Therapeutic strategies.

Publication types

  • Review

MeSH terms

  • Animals
  • Cerium / therapeutic use*
  • Disease Models, Animal
  • Geographic Atrophy / drug therapy*
  • Geographic Atrophy / metabolism
  • Humans
  • Metal Nanoparticles / therapeutic use*
  • Mice
  • Rats
  • Reactive Oxygen Species / antagonists & inhibitors*
  • Reactive Oxygen Species / metabolism
  • Wet Macular Degeneration / drug therapy
  • Wet Macular Degeneration / metabolism

Substances

  • Reactive Oxygen Species
  • Cerium
  • ceric oxide